Logo image of TCDA

TRICIDA INC (TCDA) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:TCDA - US89610F1012 - Common Stock

0.108 USD
-0.01 (-10%)
Last: 1/23/2023, 8:00:00 PM
0.084 USD
-0.02 (-22.22%)
After Hours: 1/23/2023, 8:00:00 PM

TCDA Key Statistics, Chart & Performance

Key Statistics
Market Cap6.02M
Revenue(TTM)N/A
Net Income(TTM)-133.91M
Shares55.69M
Float51.35M
52 Week High13.85
52 Week Low0.09
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.36
PEN/A
Fwd PEN/A
Earnings (Next)03-27
IPO2018-06-28
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
TCDA short term performance overview.The bars show the price performance of TCDA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

TCDA long term performance overview.The bars show the price performance of TCDA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TCDA is 0.108 USD. In the past month the price decreased by -34.62%. In the past year, price decreased by -98.91%.

TRICIDA INC / TCDA Daily stock chart

TCDA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TCDA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TCDA. Both the profitability and financial health of TCDA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TCDA Financial Highlights

Over the last trailing twelve months TCDA reported a non-GAAP Earnings per Share(EPS) of -2.36. The EPS increased by 32.38% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%44.3%
Sales Q2Q%N/A
EPS 1Y (TTM)32.38%
Revenue 1Y (TTM)N/A

TCDA Forecast & Estimates

8 analysts have analysed TCDA and the average price target is 19.72 USD. This implies a price increase of 18159.26% is expected in the next year compared to the current price of 0.108.


Analysts
Analysts45
Price Target19.72 (18159.26%)
EPS Next Y38.93%
Revenue Next YearN/A

TCDA Ownership

Ownership
Inst OwnersN/A
Ins Owners5.62%
Short Float %N/A
Short RatioN/A

About TCDA

Company Profile

TCDA logo image Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.

Company Info

TRICIDA INC

7000 Shoreline Court, Suite 201

South San Francisco CALIFORNIA 94080 US

CEO: Gerrit Klaerner

Employees: 57

TCDA Company Website

Phone: 14154297800.0

TRICIDA INC / TCDA FAQ

What does TRICIDA INC do?

Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.


What is the stock price of TRICIDA INC today?

The current stock price of TCDA is 0.108 USD. The price decreased by -10% in the last trading session.


What is the dividend status of TRICIDA INC?

TCDA does not pay a dividend.


What is the ChartMill rating of TRICIDA INC stock?

TCDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the Price/Earnings (PE) ratio of TRICIDA INC (TCDA)?

TRICIDA INC (TCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.36).


Who owns TRICIDA INC?

You can find the ownership structure of TRICIDA INC (TCDA) on the Ownership tab.